LUYE PHARMA Partners with Myung In Pharma on Lisdem Patch for Alzheimer's Disease

In a groundbreaking collaboration, LUYE PHARMA has signed a partnership agreement with Myung In Pharma, a leading South Korean pharmaceutical company, for the commercialization rights of their exclusive new drug, Lisdem transdermal patch, designed to treat the symptoms of mild to moderate Alzheimer's disease. This collaboration marks a significant step forward in addressing the global challenge of Alzheimer's disease, particularly in the context of an aging population in South Korea.

Alzheimer's disease has emerged as a major public health concern worldwide, and its prevalence continues to rise. The debilitating effects of memory loss and cognitive impairment associated with the disease present numerous challenges in its treatment. Existing therapies often face issues such as poor patient compliance, high discontinuation rates due to adverse events, and difficulties in medication management. These challenges not only impact treatment efficacy but also place a heavy burden on caregivers and society as a whole.

Lisdem transdermal patch has emerged as a frontline treatment for mild to moderate Alzheimer's disease. Unlike the currently available daily transdermal patches, Lisdem is administered twice a week, offering a lower dosing frequency that improves patient compliance. Additionally, compared to oral formulations, Lisdem transdermal patch provides a convenient and easily absorbed route of administration through the skin, making it a viable option for patients with swallowing difficulties. It is also expected to reduce the occurrence of gastrointestinal adverse effects, such as nausea and vomiting.

Myung In Pharma, a key player in the central nervous system (CNS) therapeutics field in South Korea, has a strong portfolio of products focused on this therapeutic area. LUYE PHARMA aims to develop and commercialize Lisdem transdermal patch (twice-weekly) for the global market. The product has already received market approvals in several European countries and China. Furthermore, LUYE PHARMA has established partnerships with local collaborators in multiple countries, including several European nations, Japan, China, Mexico, and Thailand, for the distribution of Lisdem transdermal patch.

The partnership between LUYE PHARMA and Myung In Pharma represents a significant advancement in the treatment of mild to moderate Alzheimer's disease. By granting the commercialization rights of Lisdem transdermal patch to Myung In Pharma, the collaboration aims to address the growing needs of the aging population in South Korea and improve patient outcomes. This innovative treatment approach offers a promising solution to enhance patient compliance, simplify medication management, and reduce gastrointestinal adverse effects. With the global prevalence of Alzheimer's disease on the rise, this collaboration holds great potential to make a positive impact on the lives of patients and their caregivers worldwide.